These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 5550418)

  • 41. A clinical evaluation of fluphenazine enanthate.
    Goldberg HL; DiMascio A; Chaudhary B
    Dis Nerv Syst; 1970 Sep; 31():Suppl:46-7. PubMed ID: 5476358
    [No Abstract]   [Full Text] [Related]  

  • 42. [Clinical experience with fluphenazine Depot].
    Vencovský E; Sedivec V; Peterová E; Baudis P; Dvoráková M
    Act Nerv Super (Praha); 1970 Jan; 12(1):49-50. PubMed ID: 5418656
    [No Abstract]   [Full Text] [Related]  

  • 43. Our experience with Moditene-Depot in chronic schizophrenia.
    Gamkrelidze ShA; Putkoradze-Gamkrelidze NA
    Act Nerv Super (Praha); 1973 Aug; 15(3):169. PubMed ID: 4769133
    [No Abstract]   [Full Text] [Related]  

  • 44. Experience with fluphenazine decanoate in the management of chronic schizophrenic outpatients.
    Gaby N; Lefkowitz D; Israel JR
    N C Med J; 1982 Sep; 43(9):641-4. PubMed ID: 6958987
    [No Abstract]   [Full Text] [Related]  

  • 45. [New approach to the long-term management of chronic psychoses].
    Graefe F
    Nervenarzt; 1968 Jun; 39(6):279-81. PubMed ID: 5712434
    [No Abstract]   [Full Text] [Related]  

  • 46. [Therapeutic trial with a long-acting phenothiazine derivative. Fluphenazine enanthate in a group of chronic schizophrenics].
    Mariátegui J; Alarcón R; Arana J; Azcárate C; Butler A
    Rev Neuropsiquiatr; 1966 Mar; 29(1):33-44. PubMed ID: 5940303
    [No Abstract]   [Full Text] [Related]  

  • 47. [Fluphenazine in low and high doses in the therapy of chronic schizophrenia. (Comparative study of 40 cases)].
    Vinci M; Livi Bacci R
    Osp Psichiatr; 1969; 37(3):371-404. PubMed ID: 5383005
    [No Abstract]   [Full Text] [Related]  

  • 48. A controlled trial of fluphenazine enanthate in hospitalized chronic schizophrenics.
    Haider I
    Br J Psychiatry; 1968 Jul; 114(512):837-41. PubMed ID: 4874164
    [No Abstract]   [Full Text] [Related]  

  • 49. Hospital experience with fluphenazine enanthate.
    Young E
    Dis Nerv Syst; 1970 Oct; 31(10):705-9. PubMed ID: 5482921
    [No Abstract]   [Full Text] [Related]  

  • 50. [Treatment of schizophrenic psychoses by sustained-action neuroleptics in psychiatric outpatients' treatment (author's transl)].
    Polácek J
    Cesk Psychiatr; 1982 Feb; 78(1):49-55. PubMed ID: 7060182
    [No Abstract]   [Full Text] [Related]  

  • 51. A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W; Boisvert D; Bradwejn J
    Psychopharmacol Bull; 1984; 20(1):108-9. PubMed ID: 6371871
    [No Abstract]   [Full Text] [Related]  

  • 52. Vitiligo-like syndrome following the use of fluphenazine enanthate.
    Rampertaap MP
    Mo Med; 1985 Jan; 82(1):24-6. PubMed ID: 3969064
    [No Abstract]   [Full Text] [Related]  

  • 53. The use of fluphenazine enanthate in an out-patient clinic.
    Kingstone E
    Int Z Klin Pharmakol Ther Toxikol; 1968 Jul; 1(5):413-6. PubMed ID: 4882607
    [No Abstract]   [Full Text] [Related]  

  • 54. The effectiveness of parenteral administration of fluphenazine decanoate in the treatment of chronic schizophrenics.
    Kurland AA; Dim BH; Olsson JE
    Dis Nerv Syst; 1970 Sep; 31():Suppl:18-23. PubMed ID: 5476356
    [No Abstract]   [Full Text] [Related]  

  • 55. Fluphenazine enanthate ... its use in the treatment of schizophrenia.
    Lavallee BW
    Can J Psychiatr Nurs; 1968 Dec; 9(10):4-6. PubMed ID: 5189479
    [No Abstract]   [Full Text] [Related]  

  • 56. Fluphenazine hydrochloride, enanthate, and decanoate in the management of chronic psychosis.
    Itil T; Keskiner A
    Dis Nerv Syst; 1970 Sep; 31():Suppl:37-42. PubMed ID: 4920313
    [No Abstract]   [Full Text] [Related]  

  • 57. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
    Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
    [No Abstract]   [Full Text] [Related]  

  • 58. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
    Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
    Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
    Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
    J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Flufenazine decanoate in the ambulatory treatment of schizophrenic patients].
    Populin M; De Vanna M; Poldrugo F
    Minerva Psichiatr; 1981; 22(2):85-92. PubMed ID: 7022095
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.